Accountable care organizations (ACOs) in the Medicare Shared Savings Program vary considerably in how they treat men with newly diagnosed prostate cancer, according to a study that assessed whether the level of engagement in ACOs by urologists could affect rates of treatment, overtreatment, and spending in prostate cancer care.
Accountable care organizations (ACOs) in the Medicare Shared Savings Program vary considerably in how they treat men with newly diagnosed prostate cancer, according to a study that assessed whether the level of engagement in ACOs by urologists could affect rates of treatment, overtreatment, and spending in prostate cancer care.
The research, published in Cancer, studied Medicare claims of men diagnosed with prostate cancer between 2012 and 2014 and followed the men through the end of 2015. The men were 66 years and older and had continuous enrollment in Medicare parts A and B for 1 year before and after a new diagnosis.
“Policies that align financial incentives with evidenced-based management (ie, those that improve value) have the potential to affect the treatment of prostate cancer,” the authors noted. “[ACOs] are emblematic of such a policy.”
However, ACOs are organized around the primary care physician, and a minority of surgeons and urologists, who may be able to influence care delivery in clinical areas such as prostate cancer, participate in ACOs.
Of the 2822 men with newly diagnosed prostate cancer assigned to an ACO, the median treatment rate was 71.3% (range, 23.6% to 79.5%). In addition, 255 men were subject to potential overtreatment, because they had a 75% or greater chance of dying within 10 years from a reason other than cancer. While there were no significant associations between race, comorbidity, or socioeconomic status and potential overtreatment, the researchers did find that younger age was associated with potential overtreatment.
The ACOs ran the gamut of urologist engagement from ACOs that had no patients with prostate cancer being managed by an ACO-participating urologist to 100% of patients with prostate cancer being treated by an ACO-participating urologist. Overall, ACO—urologist engagement was associated with reduced use of potential overtreatment for men who had a high risk of a noncancer mortality. However, urologist engagement was not significantly associated with overall treatment rate or spending in the first year after diagnosis.
“The ability of an ACO to engage urologists is associated with how often it provides prostate cancer treatment to men who are unlikely to benefit,” the authors concluded. “Further research is needed to understand how ACOs can better engage urologists, whether by improved care coordination, directed referral patterns, or modification of financial incentives.”
Reference
Modi PK, Kaufman SR, Borza T, et al. Variation in prostate cancer treatment and spending among Medicare Shared Savings Program accountable care organizations. Cancer. 2018;124(16):3364-3371. doi: 10.1002/cncr.31573.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More